Which has higher valuation and earnings, MRV or VRX?

Nuvo Pharmaceuticals has higher revenue and earnings than Valeant Pharmaceuticals International. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nuvo Pharmaceuticals C$8.72B 3.73 C$15.17M C$2.91 12.45 Valeant Pharmaceuticals International N/A N/A N/A N/A N/A

Which has better earnings and valuation, APHA or MRV?

Nuvo Pharmaceuticals has higher revenue and earnings than Aphria. Aphria is trading at a lower price-to-earnings ratio than Nuvo Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aphria C$611.06M 0.00 -C$637.39M -C$2.01 N/A Nuvo Pharmaceuticals C$8.72B 3.73 C$15.17M C$2.91 12.45

Do analysts rate BHC or MRV?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bausch Health Companies 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Nuvo Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts rate CRON or MRV?

Cronos Group currently has a consensus target price of C$4.75, indicating a potential upside of 22.11%. Given Cronos Group's stronger consensus rating and higher probable upside, equities research analysts clearly believe Cronos Group is more favorable than Nuvo Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cronos Group 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Nuvo Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable valuation and earnings, CRON or MRV?

Nuvo Pharmaceuticals has higher revenue and earnings than Cronos Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cronos Group C$159.54M 9.11 -C$32.78M N/A N/A Nuvo Pharmaceuticals C$8.72B 3.73 C$15.17M C$2.91 12.45

Nuvo Pharmaceuticals (MRV) Competitors

C$36.23 +0.79 (+2.23%)

As of 07/14/2026 03:59 PM Eastern

Compare

MRV vs. VRX, APHA, BHC, CRON, and DHT.UN

Should you buy Nuvo Pharmaceuticals stock or one of its competitors? MarketBeat compares Nuvo Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Nuvo Pharmaceuticals include Valeant Pharmaceuticals International (VRX), Aphria (APHA), Bausch Health Companies (BHC), Cronos Group (CRON), and DRI Healthcare Trust (DHT.UN). These companies are all part of the "drug manufacturers - specialty & generic" industry.

How does Nuvo Pharmaceuticals compare to Valeant Pharmaceuticals International?

Nuvo Pharmaceuticals (TSE:MRV) and Valeant Pharmaceuticals International (TSE:VRX) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations, media sentiment and valuation.

Nuvo Pharmaceuticals has higher revenue and earnings than Valeant Pharmaceuticals International.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvo Pharmaceuticals	C$8.72B	3.73	C$15.17M	C$2.91	12.45
Valeant Pharmaceuticals International	N/A	N/A	N/A	N/A	N/A

In the previous week, Nuvo Pharmaceuticals' average media sentiment score of 0.00 equaled Valeant Pharmaceuticals International'saverage media sentiment score.

Company	Overall Sentiment
Nuvo Pharmaceuticals	Neutral
Valeant Pharmaceuticals International	Neutral

1.8% of Nuvo Pharmaceuticals shares are owned by institutional investors. 6.3% of Nuvo Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Nuvo Pharmaceuticals has a net margin of 20.95% compared to Valeant Pharmaceuticals International's net margin of 0.00%. Nuvo Pharmaceuticals' return on equity of 1,180.47% beat Valeant Pharmaceuticals International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvo Pharmaceuticals	20.95%	1,180.47%	5.85%
Valeant Pharmaceuticals International	N/A	N/A	N/A

Summary

Nuvo Pharmaceuticals beats Valeant Pharmaceuticals International on 6 of the 6 factors compared between the two stocks.

How does Nuvo Pharmaceuticals compare to Aphria?

Aphria (TSE:APHA) and Nuvo Pharmaceuticals (TSE:MRV) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, media sentiment, profitability, valuation, earnings and institutional ownership.

1.8% of Nuvo Pharmaceuticals shares are owned by institutional investors. 6.3% of Nuvo Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Aphria's average media sentiment score of 0.00 equaled Nuvo Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Aphria	Neutral
Nuvo Pharmaceuticals	Neutral

Nuvo Pharmaceuticals has a net margin of 20.95% compared to Aphria's net margin of 0.00%. Nuvo Pharmaceuticals' return on equity of 1,180.47% beat Aphria's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aphria	N/A	N/A	N/A
Nuvo Pharmaceuticals	20.95%	1,180.47%	5.85%

Nuvo Pharmaceuticals has higher revenue and earnings than Aphria. Aphria is trading at a lower price-to-earnings ratio than Nuvo Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aphria	C$611.06M	0.00	-C$637.39M	-C$2.01	N/A
Nuvo Pharmaceuticals	C$8.72B	3.73	C$15.17M	C$2.91	12.45

Summary

Nuvo Pharmaceuticals beats Aphria on 9 of the 9 factors compared between the two stocks.

How does Nuvo Pharmaceuticals compare to Bausch Health Companies?

Bausch Health Companies (TSE:BHC) and Nuvo Pharmaceuticals (TSE:MRV) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, earnings, dividends, profitability, valuation and risk.

Bausch Health Companies has a beta of 0.973491, meaning that its stock price is 3% less volatile than the broader market. Comparatively, Nuvo Pharmaceuticals has a beta of 0.917796, meaning that its stock price is 8% less volatile than the broader market.

Nuvo Pharmaceuticals has a net margin of 20.95% compared to Bausch Health Companies' net margin of -13.54%. Nuvo Pharmaceuticals' return on equity of 1,180.47% beat Bausch Health Companies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch Health Companies	-13.54%	120.43%	4.16%
Nuvo Pharmaceuticals	20.95%	1,180.47%	5.85%

In the previous week, Bausch Health Companies had 1 more articles in the media than Nuvo Pharmaceuticals. MarketBeat recorded 1 mentions for Bausch Health Companies and 0 mentions for Nuvo Pharmaceuticals. Bausch Health Companies' average media sentiment score of 0.00 equaled Nuvo Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Bausch Health Companies	Neutral
Nuvo Pharmaceuticals	Neutral

11.0% of Bausch Health Companies shares are held by institutional investors. Comparatively, 1.8% of Nuvo Pharmaceuticals shares are held by institutional investors. 11.3% of Bausch Health Companies shares are held by insiders. Comparatively, 6.3% of Nuvo Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch Health Companies	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Nuvo Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Nuvo Pharmaceuticals has lower revenue, but higher earnings than Bausch Health Companies. Bausch Health Companies is trading at a lower price-to-earnings ratio than Nuvo Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch Health Companies	C$10.53B	0.24	-C$125.65M	-C$3.24	N/A
Nuvo Pharmaceuticals	C$8.72B	3.73	C$15.17M	C$2.91	12.45

Summary

Nuvo Pharmaceuticals beats Bausch Health Companies on 7 of the 13 factors compared between the two stocks.

How does Nuvo Pharmaceuticals compare to Cronos Group?

Cronos Group (TSE:CRON) and Nuvo Pharmaceuticals (TSE:MRV) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and risk.

Cronos Group currently has a consensus target price of C$4.75, indicating a potential upside of 22.11%. Given Cronos Group's stronger consensus rating and higher probable upside, equities research analysts clearly believe Cronos Group is more favorable than Nuvo Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cronos Group	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Nuvo Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Cronos Group has a beta of 1.126226, indicating that its stock price is 13% more volatile than the broader market. Comparatively, Nuvo Pharmaceuticals has a beta of 0.917796, indicating that its stock price is 8% less volatile than the broader market.

Nuvo Pharmaceuticals has a net margin of 20.95% compared to Cronos Group's net margin of -1.29%. Nuvo Pharmaceuticals' return on equity of 1,180.47% beat Cronos Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cronos Group	-1.29%	-0.19%	-3.73%
Nuvo Pharmaceuticals	20.95%	1,180.47%	5.85%

Nuvo Pharmaceuticals has higher revenue and earnings than Cronos Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cronos Group	C$159.54M	9.11	-C$32.78M	N/A	N/A
Nuvo Pharmaceuticals	C$8.72B	3.73	C$15.17M	C$2.91	12.45

In the previous week, Cronos Group had 1 more articles in the media than Nuvo Pharmaceuticals. MarketBeat recorded 1 mentions for Cronos Group and 0 mentions for Nuvo Pharmaceuticals. Cronos Group's average media sentiment score of 0.00 equaled Nuvo Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Cronos Group	Neutral
Nuvo Pharmaceuticals	Neutral

4.4% of Cronos Group shares are held by institutional investors. Comparatively, 1.8% of Nuvo Pharmaceuticals shares are held by institutional investors. 46.4% of Cronos Group shares are held by company insiders. Comparatively, 6.3% of Nuvo Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Cronos Group beats Nuvo Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Nuvo Pharmaceuticals compare to DRI Healthcare Trust?

DRI Healthcare Trust (TSE:DHT.UN) and Nuvo Pharmaceuticals (TSE:MRV) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, media sentiment, analyst recommendations, institutional ownership and profitability.

DRI Healthcare Trust has a beta of 0.385191, suggesting that its stock price is 61% less volatile than the broader market. Comparatively, Nuvo Pharmaceuticals has a beta of 0.917796, suggesting that its stock price is 8% less volatile than the broader market.

Nuvo Pharmaceuticals has higher revenue and earnings than DRI Healthcare Trust. DRI Healthcare Trust is trading at a lower price-to-earnings ratio than Nuvo Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DRI Healthcare Trust	C$163.77M	6.07	C$9.73M	-C$0.90	N/A
Nuvo Pharmaceuticals	C$8.72B	3.73	C$15.17M	C$2.91	12.45

In the previous week, DRI Healthcare Trust had 1 more articles in the media than Nuvo Pharmaceuticals. MarketBeat recorded 1 mentions for DRI Healthcare Trust and 0 mentions for Nuvo Pharmaceuticals. DRI Healthcare Trust's average media sentiment score of 1.58 beat Nuvo Pharmaceuticals' score of 0.00 indicating that DRI Healthcare Trust is being referred to more favorably in the media.

Company	Overall Sentiment
DRI Healthcare Trust	Very Positive
Nuvo Pharmaceuticals	Neutral

DRI Healthcare Trust currently has a consensus target price of C$24.80, suggesting a potential upside of 37.17%. Given DRI Healthcare Trust's stronger consensus rating and higher possible upside, equities research analysts plainly believe DRI Healthcare Trust is more favorable than Nuvo Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DRI Healthcare Trust	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.20
Nuvo Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

0.7% of DRI Healthcare Trust shares are held by institutional investors. Comparatively, 1.8% of Nuvo Pharmaceuticals shares are held by institutional investors. 0.1% of DRI Healthcare Trust shares are held by insiders. Comparatively, 6.3% of Nuvo Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Nuvo Pharmaceuticals has a net margin of 20.95% compared to DRI Healthcare Trust's net margin of 5.02%. Nuvo Pharmaceuticals' return on equity of 1,180.47% beat DRI Healthcare Trust's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DRI Healthcare Trust	5.02%	2.06%	4.22%
Nuvo Pharmaceuticals	20.95%	1,180.47%	5.85%

Summary

Nuvo Pharmaceuticals beats DRI Healthcare Trust on 10 of the 17 factors compared between the two stocks.

Get Nuvo Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MRV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

MRV vs. The Competition

Export

Metric	Nuvo Pharmaceuticals	Drug Manufacturers Industry	Medical Sector	TSE Exchange
Market Cap	C$32.52B	C$2.31B	C$6.86B	C$12.29B
Dividend Yield	0.03%	2.82%	2.68%	6.17%
P/E Ratio	12.45	5.03	26.94	36.35
Price / Sales	3.73	1,649.07	521.23	9.83
Price / Cash	0.23	10.18	48.59	82.29
Price / Book	48.31	10.40	10.89	4.49
Net Income	C$15.17M	C$20.27B	C$3.59B	C$299.09M
7 Day Performance	-3.85%	-1.01%	-1.53%	0.37%
1 Month Performance	-28.37%	-1.30%	2.72%	-1.30%
1 Year Performance	N/A	9.33%	28.47%	32.60%

Nuvo Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MRV Nuvo Pharmaceuticals	N/A	C$36.23 +2.2%	N/A	N/A	C$32.52B	C$8.72B	12.45	N/A	Gap Up
VRX Valeant Pharmaceuticals International	N/A	N/A	N/A	N/A	C$10.76B	N/A	N/A	N/A
APHA Aphria	N/A	N/A	N/A	N/A	C$5.24B	C$611.06M	N/A	1,200
BHC Bausch Health Companies	0.1718 of 5 stars	C$6.88 -1.1%	N/A	-23.0%	C$2.57B	C$10.53B	N/A	19,900
CRON Cronos Group	1.9448 of 5 stars	C$3.93 +0.5%	C$4.75 +20.9%	+37.9%	C$1.47B	C$159.54M	N/A	450

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (TSE:MRV) was last updated on 7/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nuvo Pharmaceuticals (MRV) Competitors

MRV vs. VRX, APHA, BHC, CRON, and DHT.UN

How does Nuvo Pharmaceuticals compare to Valeant Pharmaceuticals International?

Summary

How does Nuvo Pharmaceuticals compare to Aphria?

Summary

How does Nuvo Pharmaceuticals compare to Bausch Health Companies?

Summary

How does Nuvo Pharmaceuticals compare to Cronos Group?

Summary

How does Nuvo Pharmaceuticals compare to DRI Healthcare Trust?

Summary

New MarketBeat Followers Over Time

MRV vs. The Competition

Nuvo Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nuvo Pharmaceuticals (MRV) Competitors

MRV vs. VRX, APHA, BHC, CRON, and DHT.UN

How does Nuvo Pharmaceuticals compare to Valeant Pharmaceuticals International?

Which has higher valuation and earnings, MRV or VRX?

Does the media refer more to MRV or VRX?

Do insiders & institutionals have more ownership in MRV or VRX?

Is MRV or VRX more profitable?

Summary

How does Nuvo Pharmaceuticals compare to Aphria?

Do institutionals and insiders believe in APHA or MRV?

Does the media refer more to APHA or MRV?

Is APHA or MRV more profitable?

Which has better earnings and valuation, APHA or MRV?

Summary

How does Nuvo Pharmaceuticals compare to Bausch Health Companies?

Which has more volatility & risk, BHC or MRV?

Is BHC or MRV more profitable?

Does the media prefer BHC or MRV?

Do insiders and institutionals have more ownership in BHC or MRV?

Do analysts rate BHC or MRV?

Which has higher earnings and valuation, BHC or MRV?

Summary

How does Nuvo Pharmaceuticals compare to Cronos Group?

Do analysts rate CRON or MRV?

Which has more risk and volatility, CRON or MRV?

Is CRON or MRV more profitable?

Which has preferable valuation and earnings, CRON or MRV?

Does the media prefer CRON or MRV?

Do institutionals & insiders have more ownership in CRON or MRV?

Summary

How does Nuvo Pharmaceuticals compare to DRI Healthcare Trust?

Which has more volatility & risk, DHT.UN or MRV?

Which has preferable earnings and valuation, DHT.UN or MRV?

Does the media refer more to DHT.UN or MRV?

Do analysts recommend DHT.UN or MRV?

Do insiders and institutionals hold more shares of DHT.UN or MRV?

Is DHT.UN or MRV more profitable?

Summary

New MarketBeat Followers Over Time

MRV vs. The Competition

Nuvo Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools